The U.S. Continuous Glucose Market (CGM) is on a strong upward trajectory, with a compound annual growth rate (CAGR) of 9.5% through 2033. This represents a CAGR of 9.5% over the forecast period. Despite this impressive growth, the market remains significantly underpenetrated, with only about 25% of eligible patients currently using CGM systems. With a total addressable market estimated at over $20 billion, there is substantial room for expansion, particularly as awareness, accessibility, and innovation continue to improve.